According to Vikram Punia, President of the Pharmasyntez Group, the funds will launch a dedicated production section of depot drug formulations for the production of novel hormonal antineoplastic drugs and hormone antagonists.

“As part of the project, it is planned to create production of advanced and effective medications that are actively used in medicine for a range of indications: for the treatment of infertility, uterine myoma, hormone level reduction in hormone-sensitive cancers like prostate and breast cancer, some gynecological diseases like dysmenorrhea and endometriosis, elevated testosterone in women, and precocious puberty in children.”

A number of products from two therapeutic groups are included in the portfolio of medications scheduled for the production.

In a parallel move for 2025, Pharmasyntez-Tyumen plans a major overhaul of its solid dosage forms department expected to boost production capacity by 50%.